Last reviewed · How we verify
NgG high dose investigational vaccine
NgG high dose investigational vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | NgG high dose investigational vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NgG high dose investigational vaccine CI brief — competitive landscape report
- NgG high dose investigational vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about NgG high dose investigational vaccine
What is NgG high dose investigational vaccine?
NgG high dose investigational vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes NgG high dose investigational vaccine?
NgG high dose investigational vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is NgG high dose investigational vaccine in?
NgG high dose investigational vaccine is in Phase 1.